

Press Release

For further information:

Peter Friedli
Freigutstrasse 5
8002 Zürich
Tel: 044/283 29 00
Email: peter.friedli@friedlicorp.ch

New Venturetec with a loss for the period October 1, 2007 to March 31, 2008

Results for the six months period ending March 31, 2008

Zürich, May 16, 2008. New Venturetec closed the first six months for fiscal year 2007/08, ended March 31, 2008, with a loss of USD 17,352,316 compared with a profit of USD 38,257,627 in the same period 2006/07. The net asset value per share decreased from USD 26.18 to USD 22.71 which equals -13.25% during the reporting six month period. The share price in the same period decreased from CHF 21.25 to CHF 15.40, or -27.53%.

The net loss on investments of the reporting period is USD 14,978,147 compared to a gain of USD 43,253,808 in the same period 2007; the foreign exchange loss was USD 1,458,538. The main reasons for the decrease are the adjustments of the valuations of the private companies Wstore with USD 5,466,666, Iperia with USD 3,100,394 and Inflabloc Pharmaceuticals with USD 2,494,057. The details on the valuation of the privately held companies are described in the semi-annual report. The publicly held companies were influenced by the turbulences in the financial markets. The shares of Osiris Therapeutics traded -2.33% in the reporting period, which equals a loss of USD 1,138,086. The loss on Basilea Pharmaceutica was USD 1,391,291 and Invenda USD 1,187,653.

As of March 31, 2008, New Venturetec had nine investments with six investments valued higher than the investment costs and three below investment costs. The total amount of investments is USD 132'480'429 which results in an unrealized gain of USD 5,532,696. As of March 31, 2008 62.53% of the total investments are in biotechnology and 37.47% in technology. The largest position is Osiris Therapeutics (NASDAQ:OSIR) with 37.64% of total investments.

There was no management fee or board remuneration paid for the reporting period but rather accrued; USD 88,653 of the accrued management fee was paid. Total operational costs for the first half of the fiscal year 2007/08 were USD 217,411; the accrued management fee was USD 903,124.

The semi-annual report, including financial statements for the reporting period can be downloaded from www.newventuretec.com.

New Venturetec is a publicly traded Swiss investment company (SWX:NEV) which invests directly in venture capital companies predominantly in the USA in the areas biotechnology and technology.